指南与共识血脂与心血管预防

他汀一级预防指南的成本效益评估

Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
指南 / 共识 · Circulation · 2017-07-07

该研究采用心血管疾病政策模型,比较2013年ACC/AHA指南与ATP III指南及普遍他汀使用在2016至2025年间的成本效益。结果显示ACC/AHA指南较ATP III指南覆盖更多人群、挽救更多生命且成本更低,但个体获益更多取决于每日服药负担而非心血管风险程度。

要点

  • 个体长期获益更多取决于服药负担所致失能而非心血管风险水平。

核心结论

  • 在人群水平上,2013年ACC/AHA扩大他汀一级预防的指南与ATP III指南相比,在男女中均预计治疗更多人群、挽救更多生命且成本更低。

研究设计与样本

  • 采用心血管疾病政策模型,评估2016至2025年10年时间范围内ACC/AHA指南相对于当前使用、ATP III指南及普遍他汀使用的成本效益。
  • 敏感性分析变动了成本、风险和获益参数。

主要发现

  • 在所有情况下,男性的获益大于女性。
  • 结果随他汀启用风险阈值和他汀毒性估计不同而中度变化,但极大取决于每日服药所致失能(服药负担)。

临床怎么用

  • 在人群层面,ACC/AHA指南扩大他汀一级预防较ATP III指南治疗更多人群、挽救更多生命且成本更低。
  • 个体是否从长期他汀一级预防中获益更多取决于服药负担相关失能而非心血管风险程度。

局限性

  • 结果随他汀启用风险阈值和他汀毒性估计不同而中度变化,并极大取决于每日服药所致失能(服药负担)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Statins are effective in the primary prevention of atherosclerotic cardiovascular disease. The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline expands recommended statin use, but its cost-effectiveness has not been compared with other guidelines. METHODS: We used the Cardiovascular Disease Policy Model to estimate the cost-effectiveness of the ACC/AHA guideline relative to current use, Adult Treatment Panel III guidelines, and universal statin use in all men 45 to 74 years of age and women 55 to 74 years of age over a 10-year horizon from 2016 to 2025. Sensitivity analyses varied costs, risks, and benefits. Main outcomes were incremental cost-effectiveness ratios and numbers needed to treat for 10 years per quality-adjusted life-year gained. RESULTS: Each approach produces substantial benefits and net cost savings relative to the status quo. Full adherence to the Adult Treatment Panel III guideline would result in 8.8 million more statin users than the status quo, at a number needed to treat for 10 years per quality-adjusted life-year gained of 35. The ACC/AHA guideline would potentially result in up to 12.3 million more statin users than the Adult Treatment Panel III guideline, with a marginal number needed to treat for 10 years per quality-adjusted life-year gained of 68. Moderate-intensity statin use in all men 45 to 74 years of age and women 55 to 74 years of age would result in 28.9 million more statin users than the ACC/AHA guideline, with a marginal number needed to treat for 10 years per quality-adjusted life-year gained of 108. In all cases, benefits would be greater in men than women. Results vary moderately with different risk thresholds for instituting statins and statin toxicity estimates but depend greatly on the disutility caused by daily medication use (pill burden). CONCLUSIONS: At a population level, the ACC/AHA guideline for expanded statin use for primary prevention is projected to treat more people, to save more lives, and to cost less compared with Adult Treatment Panel III in both men and women. Whether individuals benefit from long-term statin use for primary prevention depends more on the disutility associated with pill burden than their degree of cardiovascular risk.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Heller DJ, Coxson PG, Penko J, et al. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke. Circulation. 2017. PMID: 28687710. doi:10.1161/CIRCULATIONAHA.117.027067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。